FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches

Peter-James H. Zushin(Cardiovascular Institute of the South), Souhrid Mukherjee, Joseph C. Wu(Cardiovascular Institute of the South)
Journal of Clinical Investigation
October 31, 2023
10.1172/jci175824
Cited by 273Open Access
Full Text

Abstract

Related Papers

Clinical development success rates for investigational drugs
Michael Hay, David W. Thomas, John L. Craighead et al.|Nature Biotechnology|2014|2.5k
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Ganesh Suntharalingam, Meghan Perry, Stephen Ward et al.|New England Journal of Medicine|2006|2.1k
Believe it or not: how much can we rely on published data on potential drug targets?
Florian Prinz, Thomas Schlange, Khusru Asadullah|Nature Reviews Drug Discovery|2011|1.9k
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Michael J. Waring, John Arrowsmith, Andrew R. Leach et al.|Nature Reviews Drug Discovery|2015|1.4k
Personalized medicine: Time for one-person trials
Nicholas J. Schork|Nature|2015|1.2k